The stock of Chimerix Inc (NASDAQ: CMRX) has decreased by -0.06 when compared to last closing price of 8.48. Despite this, the company has experienced a 0.18% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-03-10 that NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharmaceuticals plc. (NasdaqGS: JAZZ). Under the terms of the proposed transaction, shareholders of Chimerix will receive $8.55 in cash for each share of Chimerix that they own. KSF is seeking to determine whether this consideration and the process that led to.
Is It Worth Investing in Chimerix Inc (NASDAQ: CMRX) Right Now?
The 36-month beta value for CMRX is at -0.17. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for CMRX is 78.69M, and currently, shorts hold a 6.01% of that float. The average trading volume for CMRX on March 19, 2025 was 4.05M shares.
CMRX’s Market Performance
CMRX’s stock has seen a 0.18% increase for the week, with a 75.47% rise in the past month and a 187.29% gain in the past quarter. The volatility ratio for the week is 0.26%, and the volatility levels for the past 30 days are at 4.74% for Chimerix Inc The simple moving average for the last 20 days is 23.38% for CMRX stock, with a simple moving average of 295.38% for the last 200 days.
Analysts’ Opinion of CMRX
Many brokerage firms have already submitted their reports for CMRX stocks, with Robert W. Baird repeating the rating for CMRX by listing it as a “Outperform.” The predicted price for CMRX in the upcoming period, according to Robert W. Baird is $7 based on the research report published on May 23, 2023 of the previous year 2023.
CapitalOne, on the other hand, stated in their research note that they expect to see CMRX reach a price target of $7. The rating they have provided for CMRX stocks is “Overweight” according to the report published on September 07th, 2022.
Maxim Group gave a rating of “Buy” to CMRX, setting the target price at $20 in the report published on April 29th of the previous year.
CMRX Trading at 65.50% from the 50-Day Moving Average
After a stumble in the market that brought CMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.06% of loss for the given period.
Volatility was left at 4.74%, however, over the last 30 days, the volatility rate increased by 0.26%, as shares surge +66.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +134.12% upper at present.
During the last 5 trading sessions, CMRX rose by +0.18%, which changed the moving average for the period of 200-days by +779.24% in comparison to the 20-day moving average, which settled at $6.87. In addition, Chimerix Inc saw 143.53% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMRX starting from Melemed Allen S., who sale 3,065 shares at the price of $4.50 back on Feb 13 ’25. After this action, Melemed Allen S. now owns 152,875 shares of Chimerix Inc, valued at $13,799 using the latest closing price.
Andriole Michael T., the PRESIDENT AND CEO of Chimerix Inc, sale 7,370 shares at $4.52 during a trade that took place back on Feb 13 ’25, which means that Andriole Michael T. is holding 609,603 shares at $33,282 based on the most recent closing price.
Stock Fundamentals for CMRX
Current profitability levels for the company are sitting at:
- -583.81 for the present operating margin
- -132.86 for the gross margin
The net margin for Chimerix Inc stands at -525.75. The total capital return value is set at -0.68. Equity return is now at value -48.59, with -43.54 for asset returns.
Based on Chimerix Inc (CMRX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -109.39. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -32.62.
Currently, EBITDA for the company is -92.97 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 4811.99. The receivables turnover for the company is 1.03for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.33.
Conclusion
In conclusion, Chimerix Inc (CMRX) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
